# Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

> **NCT04224415** · PHASE2 · COMPLETED · sponsor: **Yuhong Li** · enrollment: 35 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** C225+CPT-11

## Key facts

- **NCT ID:** NCT04224415
- **Lead sponsor:** Yuhong Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-31
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04224415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04224415, "Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04224415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*